Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808667 | 0.88 | SIGMAR1 (0.57) | SIGMAR1MC4RALDH1A1LMNADRD4 | |
| SCHEMBL60814 | 0.87 | SIGMAR1 (0.74) | SIGMAR1MC4RLMNADRD4KDM4E | |
| SCHEMBL155000 | 0.82 | SIGMAR1 (0.65) | SIGMAR1MC4RALDH1A1LMNADRD4 | |
| SCHEMBL5170509 | 0.82 | CASP1 (0.49) | ALDH1A1LMNAKDM4EPOLBACHE | |
| SCHEMBL2178931 | 0.82 | MAOA (0.68) | SIGMAR1MC4RALDH1A1LMNADRD4 | |
| SCHEMBL3333802 | 0.80 | MAOA (0.49) | ALDH1A1KDM4EPOLBACHEBCHE | |
| SCHEMBL7204490 | 0.80 | HPGD (0.46) | ALDH1A1KDM4EPOLBCYP3A4KMT2A | |
| SCHEMBL6989203 | 0.80 | SIGMAR1 (0.63) | SIGMAR1MC4RALDH1A1LMNADRD4 | |
| SCHEMBL29101920 | 0.80 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4EPOLBACHE | |
| SCHEMBL6397596 | 0.80 | MAOA (0.71) | SIGMAR1ACHECCR3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | claimed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | claimed |
| CN-109923108-B | Pyridyl-substituted indole compounds | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | claimed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | claimed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | claimed |
| CN-1081676-A | The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application | SANKYO CO (JP) | 1994-02-09 | — | — | CN | claimed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0566142-A1 | Inclusion complexes of optically active and racemic 1,4-dihydro pyridines with cyclodextrin derivates | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1993-10-20 | — | — | EP | claimed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0403957-A2 | Optical active 1,4-dihydropyridine derivates | FUJIREBIO INC. (JP) | 1990-12-27 | — | — | EP | claimed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | claimed |
| EP-0320984-A2 | 1,4-Dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1989-06-21 | — | — | EP | claimed |
| EP-0001643-A2 | Aminoglycoside derivatives, process for their manufacture, pharmaceutical compositions and carboxylic acids | SHIONOGI & CO., LTD. (JP) | 1979-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | SIGMAR1 1079/4885MC4R 999/4885ALDH1A1 4711/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | SIGMAR1 3814/4885MC4R 2468/4885ALDH1A1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.